<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="article-commentary"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24795860</article-id><article-id pub-id-type="pmc">4001053</article-id><article-id pub-id-type="doi">10.3389/fonc.2014.00083</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>General Commentary</subject></subj-group></subj-group></article-categories><title-group><article-title>Corrigendum: Involvement of a Non-Human Sialic Acid in Human Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Samraj</surname><given-names>Annie N.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/137459"/></contrib><contrib contrib-type="author"><name><surname>L&#x000e4;ubli</surname><given-names>Heinz</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Varki</surname><given-names>Nissi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Varki</surname><given-names>Ajit</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/131673"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Departments of Medicine, Pathology and Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California San Diego</institution>, <addr-line>La Jolla, CA</addr-line>, <country>USA</country></aff><author-notes><fn fn-type="edited-by"><p>Edited and reviewed by: Adriane Regina Todeschini, Universidade Federal do Rio de Janeiro, Brazil</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: <email>a1varki@ucsd.edu</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>4</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>4</volume><elocation-id>83</elocation-id><history><date date-type="received"><day>02</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>04</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Samraj, L&#x000e4;ubli, Varki and Varki.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="commentary-article" id="d35e129" vol="4" page="33" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="24600589" ext-link-type="pubmed">A corrigendum on <article-title>Involvement of a non-human sialic acid in human cancer</article-title> by Samraj AN, L&#x000e4;ubli H and Varki A. Front Oncol (2014) 4:33. doi: 10.3389/fonc.2014.00033</related-article><kwd-group><kwd>Neu5Gc</kwd><kwd>sialic acid</kwd><kwd>antibodies</kwd><kwd>inflammation</kwd><kwd>tumor antigen</kwd><kwd>red meat</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="3"/><page-count count="1"/><word-count count="477"/></counts></article-meta></front><body><p>Antibodies 14F7 and the corresponding anti-idiotype 1E10 (racotumomab, misspelled as racotumumab) were mistakenly conflated in this review. 14F7 reacts with (Neu5Gc)GM3, was recently humanized (<xref rid="B1" ref-type="bibr">1</xref>), but has not yet been tested in clinical trials. Racotumomab induced a human anti-(Neu5Gc)GM3 immune response, which correlated with longer median survival in non-small cell lung cancer (<xref rid="B2" ref-type="bibr">2</xref>). The first clinical trial result using racotumomab was actually published in 2002 (<xref rid="B3" ref-type="bibr">3</xref>). A phase III trial testing racotumomab in advanced non-small cell lung cancer began in 2011, and is currently recruiting (NCT01460472). These studies do not consider dietary Neu5Gc intake and incorporation as a variable that could affect (Neu5Gc)GM3 expression by human cancers.</p><sec id="S1"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Marrero</surname><given-names>Y</given-names></name><name><surname>Roque-Navarro</surname><given-names>L</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>T</given-names></name><name><surname>Dorvignit</surname><given-names>D</given-names></name><name><surname>Molina-P&#x000e9;rez</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates</article-title>. <source>Immunobiology</source> (<year>2011</year>) <volume>216</volume>:<fpage>1239</fpage>&#x02013;<lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2011.07.004</pub-id><pub-id pub-id-type="pmid">21802167</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>AM</given-names></name><name><surname>Toledo</surname><given-names>D</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>D</given-names></name><name><surname>Gri&#x000f1;&#x000e1;n</surname><given-names>T</given-names></name><name><surname>Brito</surname><given-names>V</given-names></name><name><surname>Mac&#x000ed;as</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<fpage>6625</fpage>&#x02013;<lpage>34</lpage><pub-id pub-id-type="pmid">18941253</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfonso</surname><given-names>M</given-names></name><name><surname>D&#x000ed;az</surname><given-names>A</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>AM</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>A</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>E</given-names></name><name><surname>Bitton</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>168</volume>:<fpage>2523</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">11859147</pub-id></mixed-citation></ref></ref-list></back></article>